Thrombosis and haemostasis最新文献

{"title":"Risk of Major Bleeding with Antiplatelet and/or Anticoagulation Therapy in Inherited Factor XI Deficiency: Insights from Real-World Observations.","authors":"Shanni Vaismann, Nili Stein, Liat Dizengoff, Amir Warwar, Shoshan Perek, Ibraheem Zoabi, Walid Saliba, Meir Preis","doi":"10.1055/a-2347-4338","DOIUrl":"10.1055/a-2347-4338","url":null,"abstract":"","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"82-84"},"PeriodicalIF":5.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141421098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation: Rationale and Design for PRESTIGE-AF Trial.","authors":"Eleni Korompoki, Peter Heuschmann, Kirsten H Harvey, Cornelia Fiessler, Uwe Malzahn, Klemens Hügen, Sabine Ullmann, Gabriele Putz Todd, Carolin Schuhmann, Joan Montaner, Igor Sibon, Stephanie Debette, Christian Enzinger, Stefan Ropele, Viktoria Rücker, Kirsten Haas, Emily Harvey, Charles Wolfe, Yanzhong Wang, Peter B Nielsen, Valeria Caso, Gregory Y H Lip, Deirdre A Lane, Omid Halse, Peter Ringleb, Walter E Haefeli, Kathrin I Foerster, Viktoria S Wurmbach, Roland Veltkamp","doi":"10.1055/a-2496-5492","DOIUrl":"https://doi.org/10.1055/a-2496-5492","url":null,"abstract":"<p><p>Adequate secondary prevention in survivors of intracerebral hemorrhage (ICH) who also have atrial fibrillation (AF) is a long-standing clinical dilemma because these patients are at increased risk of recurrent ICH as well as of ischemic stroke. The efficacy and safety of oral anticoagulation, the standard preventive medication for ischemic stroke patients with AF, in ICH patients with AF are uncertain. PRESTIGE-AF is an international, phase 3b, multi-center, randomized, open, blinded end-point assessment (PROBE) clinical trial that compared the efficacy and safety of direct oral anticoagulants (DOACs) with no DOAC (either no antithrombotic treatment or any antiplatelet drug). Randomization occurred in a 1:1 ratio and stratification was based on ICH location and sex. The two co-primary binary endpoints included ischemic stroke and recurrent ICH which will be analyzed hierarchically according to the intention-to-treat principle. Secondary efficacy endpoints encompassed all-stroke and systemic embolism, all-cause and cardiovascular mortality, major adverse cardiac events, and net clinical benefit. Secondary safety endpoints included any major hemorrhage and intracranial hemorrhage. All outcome events were adjudicated by an independent committee. Results of PRESTIGE-AF are expected to support risk-adjusted secondary prevention in ICH survivors with AF and to inform clinical guideline recommendations.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142910714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophil Extracellular Traps, Platelets and Endothelial Cells Cooperatively Contribute to Hypercoagulability in Non-Small Cell Lung Cancer.","authors":"Dongxia Tong, Yuan Gao, Weihua Sun, Jie Yang, Yang Liu, Jihe Li, Yan Zhang","doi":"10.1055/a-2493-2499","DOIUrl":"10.1055/a-2493-2499","url":null,"abstract":"<p><strong>Background: </strong> Thromboembolism is the second leading cause of death among patients with non-small cell lung cancer (NSCLC), but the precise mechanisms of thrombogenesis in NSCLC remain largely unknown. Our objectives were to evaluate the definitive role of neutrophil extracellular traps (NETs) in the hypercoagulability in NSCLC and to explore its interactions with platelets and endothelial cells (ECs).</p><p><strong>Methods: </strong> The levels of NET markers in samples from 100 NSCLC patients and 30 healthy controls were measured by ELISA. NET formation was detected using immunofluorescence. Procoagulant activity was assessed based on purified coagulation complex, thrombin, clotting time, and fibrin formation assays.</p><p><strong>Results: </strong> The plasma levels of NETs were increased in a stage-dependent manner in NSCLC patients and were markedly higher than those in controls. Neutrophils from NSCLC patients were more prone to form NETs, resulting in shortened coagulation time, significantly increased thrombin-antithrombin complexes and fibrin compared to controls. Moreover, NETs generation was mediated by High Mobility Group Box 1 from activated platelets in NSCLC patients. Conversely, NETs from NSCLC patients also induce phosphatidylserine exposure on platelets, leading to markedly enhanced procoagulant activity (PCA). Furthermore, NETs can damage endothelial cells and convert them to a procoagulant phenotype. The administration of NETs inhibitors (DNase I/activated protein C) could markedly diminish the PCA of NETs, activated platelets, and ECs.</p><p><strong>Conclusion: </strong> Our results suggest that NETs contribute to hypercoagulability and may represent a potential therapeutic target to prevent cancer-associated thrombosis in NSCLC patients.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C-reactive Protein, Genetic Susceptibility, and the Long-Term Risk of Venous Thromboembolism in Patients with Past Cancer.","authors":"Yunlong Guan, Zeyu Gan, Si Li, Xi Cao, Ao Zeng, Jing Li, Wei Gong, Jun Deng, Xingjie Hao","doi":"10.1055/a-2495-1350","DOIUrl":"10.1055/a-2495-1350","url":null,"abstract":"<p><strong>Background: </strong> Several studies have indicated that C-reactive protein (CRP) level is associated with the risk of venous thromboembolism (VTE) in the general population. However, CRP appears to be unrelated to VTE events in patients newly diagnosed with cancer. As the survival time of cancer patients increases, the effect of CRP on the long-term risk of VTE may change. We aimed to investigate the association between CRP and VTE in cancer survivors and further assess the modification effect of genetic susceptibility.</p><p><strong>Methods: </strong> The Cox proportional hazards model was used to evaluate the association between CRP levels and VTE risk as well as to investigate the joint effect of CRP and genetic susceptibility. The Kaplan-Meier curve and restricted cubic spline were used to visualize the relationship between CRP and VTE.</p><p><strong>Results: </strong> This study included 27,806 participants with cancer diagnosis at baseline in the UK Biobank. Over a follow-up period of 344,636 person-years, a total of 1,151 VTE events were recorded. Participants were divided into four groups based on CRP level quartiles. The adjusted hazard ratios (95% CIs) of Q1, Q2, Q3, and Q4 were 1.00, 1.20 (0.99-1.44), 1.25 (1.04-1.50), and 1.51 (1.25-1.82), respectively. For those with high genetic risk of VTE, high CRP had an additional increased risk for VTE.</p><p><strong>Conclusion: </strong> CRP can be used as a predictive biomarker for VTE risk in cancer survivors, especially in those with high genetic risk. Future research can explore whether prevention and treatment strategies for VTE can be developed based on CRP for cancer survivors.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activation of the contact system and intrinsic pathway in peripheral and portal venous circulations in liver cirrhosis.","authors":"Elena Campello, Alberto ZAnetto, Yuriy Prokopenko, Anton Ilich, Chatphatai Moonla, Cristiana Bulato, Serena Toffanin, Sarah Shalaby, Romilda Cardin, Giulio Barbiero, Sabrina Gavasso, Nigel S Key, Marco Senzolo, Paolo Simioni","doi":"10.1055/a-2507-2449","DOIUrl":"https://doi.org/10.1055/a-2507-2449","url":null,"abstract":"<p><strong>Background: </strong>Portal vein system-specific risk factors contributing to portal vein thrombosis in cirrhosis are poorly investigated.</p><p><strong>Aims: </strong>To quantify contact system and intrinsic pathway activation in peripheral compared to portal venous blood in patients with decompensated cirrhosis.</p><p><strong>Methods: </strong>Adult patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt underwent simultaneous blood sampling from a peripheral vein and the portal vein. Complexes of serine proteases with their respective inhibitors were measured by ELISA to quantify contact system (PKa:C1INH [kallikrein:C1-esterase inhibitor] and FXIIa:C1INH) and intrinsic pathway activation (FXIa:C1INH, FXIa:α1at [alpha-1 antitrypsin], FXIa:AT [antithrombin], and FIXa:AT).</p><p><strong>Results: </strong>Twenty patients with cirrhosis (mean age 55 ± 7 years, M=58%, Child-Pugh A/B/C 6/11/3) and 25 healthy controls (mean age 45 ± 12 years, M=60%) were enrolled. Aetiology of cirrhosis was primarily alcohol abuse, followed by chronic viral infection. Log-transformed peripheral levels of all the complexes were significantly higher in patients compared with controls. While levels of PKa:C1 INH, FXIIa:C1 INH, FXIa:C1 INH and FXIa:α1at were similar in peripheral and portal venous blood in cirrhotic patients, FXIa:AT and FIXa:AT levels were significantly higher in portal blood (p = 0.013 and 0.011, respectively). FXIa:C1 INH significantly correlated with both contact system complexes (FXIIa:C1 INH and PKa:C1 INH) and with FIX:AT.</p><p><strong>Conclusions: </strong>Markers of contact system and intrinsic pathway activation in the systemic circulation were significantly higher in cirrhosis vs. controls. Complexes of FXIa and FIXa with AT were significantly higher in the portal than in peripheral plasma in cirrhosis, possibly indicating unique heparin-like effect in portal venous blood.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gene correction of Wiskott-Aldrich-syndrome iPS cells rescues proplatelet defects and improves platelet size.","authors":"Praewphan Ingrungruanglert, Sarinya Phodang, Pramuk Amarinthnukrowh, Phattarawan Meehart, Pornpitra Pratedrat, Narissara Suratannon, Vorasuk Shotelersuk, Kanya Suphapeetiporn, Nipan Israsena","doi":"10.1055/a-2508-0983","DOIUrl":"https://doi.org/10.1055/a-2508-0983","url":null,"abstract":"<p><p>Wiskott-Aldrich syndrome (WAS) is a severe X-linked disorder caused by loss-of-function mutations in the WAS gene, responsible for encoding WASP, a key regulator of actin cytoskeleton in all hematopoietic cells except red blood cells. The mechanism underlying microthrombocytopenia, a distinctive feature of WAS and a major contributor to mortality, remains not fully elucidated. In this study, using different gene editing strategies, we corrected mutations in patient-derived WAS-induced pluripotent stem cell lines, generating isogeneic WAS iPSC lines. These included lines with direct mutation-specific correction and lines incorporating a WASP transgene cassette regulated by the MND or WAS1.6 kb promoter integrated at the safe harbor AAV1 site. Our results demonstrated that direct mutation correction successfully restored WASP levels to the equivalent of wild-type in iPSC-derived megakaryocytes. In contrast, the AAV1-targeted strategy using the MND and WAS1.6 promoter yielded a lower level of WASP. Notably, only the mutation-specific correction lines exhibited improvements in proplatelet structures and generated larger-sized platelets. Our findings underscore the crucial roles of WASP during human thrombopoiesis and suggest that therapeutic approaches, such as direct gene correction, which can achieve physiologic levels of WASP in megakaryocytes, hold promise for ameliorating platelet defects in individuals with WAS.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit.","authors":"Dimpy Modi, Saifur Rahman Chowdhury, Syed Mahamad, Hayley Modi, Douglas Cines, Cindy Neunert, Hanny Al-Samkari, Nichola Cooper, Guillaume Moulis, Charlotte Cunningham-Rundles, Howard Liebman, James B Bussel, Vicky R Breakey, Ishac Nazy, Donald M Arnold","doi":"10.1055/a-2508-1112","DOIUrl":"https://doi.org/10.1055/a-2508-1112","url":null,"abstract":"<p><p>The McMaster Immune Thrombocytopenia (ITP) Summit was an educational seminar from leading experts in immune thrombocytopenia and related disorders geared towards hematologists, internists, immunologists, and clinical and translational scientists. The focus of the Summit was to review the mechanisms, diagnosis and treatment of primary versus secondary ITP. Specific objectives were to describe the unique features of secondary ITP, and to review its mechanisms in the context of autoimmune disease and infection. The key messages in this Summit were: (1) ITP is a heterogeneous disease, and genetic and immunologic insights may help classify patient subtypes; (2) Exploring the autoimmune mechanisms and their association with hypogammaglobulinemia in patients with secondary ITP could improve our understanding of ITP and its subtypes; (3) Investigating the mechanisms of ITP in the context of infections caused by viruses such as CMV, HIV, dengue, and hepatitis C, or bacteria such as H. pylori, or vaccinations could provide insight into the causes of ITP. A better understanding of secondary ITP could help elucidate the pathogenesis of ITP.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dabigatran Attenuates the Binding of Thrombin to Platelets-A Novel Mechanism of Action.","authors":"Tomas L Lindahl, Aishwarya Prasanna Kumar, Teresia Hallström, Ahmed Al-Hashimi, Anna du Rietz, Elena Arlaman, Kajsa Uvdal, Ankit S Macwan","doi":"10.1055/a-2483-0107","DOIUrl":"10.1055/a-2483-0107","url":null,"abstract":"<p><strong>Background: </strong> Thrombin is a multifunctional regulatory enzyme of the haemostasis and has both pro- and anticoagulant roles. It has, therefore, been a main target for drug discovery over many decades. Thrombin is a serine protease and possesses two positively charged regions called exosites, through which it is known to bind to many substrates. Dabigatran is a thrombin inhibitor and is widely used as an oral anticoagulant for the antithrombotic treatment of atrial fibrillation and venous thromboembolism. The mechanism by which dabigatran inhibits thrombin is the blockage of the active site, however, its effect on thrombin binding to its substrates has not been studied thoroughly and is thus poorly understood.</p><p><strong>Material and methods: </strong> The effect of dabigatran on thrombin binding to platelets was evaluated by flow cytometry using fluorescently labelled thrombin and washed platelets. Further, to confirm the results we utilized modern techniques for biomolecular binding studies, microscale thermophoresis (MST) and surface plasmon resonance (SPR), which validated the results.</p><p><strong>Results: </strong> Dabigatran inhibited thrombin binding to platelets as analysed by flow cytometry. The inhibition was dose dependent with IC50 of 118 nM which was slightly lower than for inhibition of platelet activation and is close to the clinically relevant plasma concentration of dabigatran. MST and SPR also confirmed inhibitory effect of dabigatran on thrombin binding to platelets.</p><p><strong>Conclusion: </strong> Apart from blocking the active site, dabigatran also inhibits thrombin binding to platelets. Since thrombin has numerous functions beyond the cardiovascular system, this finding may have important implications.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socio-Economic Burden of Pulmonary Embolism in Europe: Shifting Priorities and Challenges for Novel Reperfusion Strategies.","authors":"Katharina Mohr, Thomas Neusius, Stefano Barco, Stavros Konstantinides","doi":"10.1055/a-2505-8711","DOIUrl":"https://doi.org/10.1055/a-2505-8711","url":null,"abstract":"<p><p>In-hospital case-fatality related to acute pulmonary embolism (PE) has been falling since the beginning of this century. However, annual incidence rates continue to climb, and an increasing number of PE survivors need long-term follow-up, chronic anticoagulation treatment and readmission(s) to the hospital. In European countries, median reimbursed hospital costs for acute PE are still moderate compared to the US, but can increase several-fold in patients with comorbidities and those necessitating potentially life-saving reperfusion treatment. Use of catheter-directed treatment (CDT) has constantly increased in the US since the past decade, and it has now entered a rapid growth phase in Europe as well, estimated to reach an annual penetration rate as high as 31% among patients with intermediate-high- or high-risk PE by 2030. Ongoing randomised controlled trials are currently investigating the clinical efficacy and safety of these devices. In addition, they will deliver data permitting calculation of their cost effectiveness in different healthcare reimbursement systems, by revealing the extent to which they can reduce complications and consequently the need for intensive care and the overall length of hospital stay. After discharge, key cost drivers are related to chronic cardiopulmonary diseases (other than PE itself) leading to frequent readmissions, and to persisting symptoms and functional limitation which result in poor quality of life, productivity loss, and substantial indirect costs. Implementation of structured outpatient programmes with a holistic approach to post PE care, targeting overall cardiovascular health and the patients' well-being, bears the potential to cost-effectively reduce the overall socio-economic burden of PE.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous Thromboembolism at Low Risk of Recurrence in Young Women: Stress and Violence Associated with Recurrence. An International Case-Control Study.","authors":"Victoria Bitsadze, Mariya Gennadevna Nikolaeva, Ève Mousty, Jamilya Khizroeva, Jérémy Laurent, Sylvie Ripart, Ekaterina Kudryavtseva, Lorris Le Collen, Anastasia Shatilina, Salim Allal, Elizaveta Lyadnova, Mathieu Fortier, Sylvie Bouvier, Mathias Chea, Marina Sabirovna Zainulina, Antonia Perez-Martin, Alexander Makatsariya, Jean-Christophe Gris","doi":"10.1055/a-2484-0923","DOIUrl":"https://doi.org/10.1055/a-2484-0923","url":null,"abstract":"<p><strong>Background: </strong> In young women with venous thromboembolism (VTE) related to weak transient risk factors, it remains unknown whether stress levels and intimate partner violence (IPV) are associated with recurrence. The VTE-WEAK study aims to investigate the association between perceived stress and IPV with a recurrence of VTE in women with a first episode of VTE due to combined oral contraceptives, pregnancy-puerperium, minor trauma/fracture, brief surgery, infection or brief immobility, and not using antithrombotic prophylaxis.</p><p><strong>Material and methods: </strong> We performed a multicenter, international, observational, retrospective study on women referred for thrombophilia screening who were subsequently monitored. Patients were aged 18 to 55 years old and free of high-risk thrombophilia. When a recurrence of VTE was suspected for the first time, the perceived stress level and IPV were evaluated using self-administrated PSS-10 and Woman Abuse Screening Tool (WAST) questionnaires.</p><p><strong>Results: </strong> We monitored 7,754 women over 43,880 patients-years. A first suspected recurrence occurred in 4,772 women, among whom 1,316 had an objectively confirmed recurrence. The perceived stress level and an IPV situation were both independent risk factors for recurrence: moderate stress: adjusted odds ratio (aOR) 1.630 (1.415-2.468); high perceived stress: aOR 10.03 (7.528-13.36); IPV: 1.953 (1.546-2.468), <i>p</i> < 0.0001.</p><p><strong>Conclusion: </strong> The perceived level of stress and IPV are associated with a recurrence of VTE when suspected. The mechanisms and clinical consequences of a possible stress coagulopathy require investigation.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}